Sylvester Comprehensive Cancer Center and Fox Chase Cancer Center Collaborate with Pfizer’s Institute of Translational Equitable Medicine to Identify New Genetic Drivers of Cancer Disparities in African-Descent Populations

  • The collaboration utilizes the African-Caribbean Cancer Consortium. The Afro-Caribbean Cancer Consortium is a multi-institutional and transcontinental network of scientists, oncologists, and health professionals focused on understanding cancer risks and outcomes for people of African descent.
  • The overarching goal of this study is to create an ethnically diverse patient cancer genome registry, expand existing resources, and explore the social determinants of health research in patients of African descent through genomics, molecular epidemiology, and health research in African oncology patients. To improve health equity.

MIAMI & FILDELPHIA, Nov. 10, 2022 — The Sylvester Comprehensive Cancer Center and Fox Chase Cancer Center today announced a collaboration with Pfizer’s Translational Equitable Medicines (ITEM) to develop a novel genetic pathway for cancer. , initiated cancer genomics studies to characterize molecular and social determinants. An entire population of African ancestry.

Dr. Sophia HL George, Sylvester’s Associate Director of Diversity, Equity and Inclusion, said: She is part of the Comprehensive Cancer Center, University of Miami Health System, and co-leader of the African-Caribbean Cancer Consortium (AC3) Women’s Cancer Working Group. Despite the high unmet need, there are a limited number of statistically supported research studies investigating cancer risk and outcomes in people of African descent.

To address these knowledge gaps, this collaboration will build a clinic genomic registry of biological specimens with epidemiological, behavioral, and clinical data from patients of African descent diagnosed with breast and prostate cancer. increase. Leveraging the global reach of the AC3 network, the team will recruit patients from ethnically, geographically and socioeconomically diverse subpopulations across the African diaspora. U.S.-born, U.S.-resident immigrant black patients, and patients from middle- and low-income countries in the Caribbean. , and patients from countries west, east, and south of the African subcontinent.

The scientific objectives of this study include: 1) identifying somatic and rare pathogenic germline gene drivers in cancer using paired tumor and normal whole-exome sequencing; These include determining inherited cancer risk using gene panel testing of known cancer drivers, and 3) characterizing hormone receptor status using immunohistochemistry. , and 4) indicate the major socioeconomic and lifestyle factors that influence cancer outcomes in patients of African descent.

“We established the Translational Equitable Medicine Institute to improve health by preventing, treating and identifying disease drivers that disproportionately affect underserved minorities nationally and globally. Our goal is to use data to better understand the drivers of health inequalities,” said Pfizer Chief Medical Officer and Worldwide Medical & Safety. Aida Habtezion, MD, MSc, FRCPC, AGAF, Director of “Fox works with Chase Cancer Center, Sylvester Comprehensive Cancer Center, and the African-Caribbean Cancer Consortium to apply scientific knowledge to disparities in disease incidence, prevalence, and outcomes among cancer patients of African descent. I’m excited to start closing the gap in doing so.”

“This registry will provide access to the limited data available to blacks, including genetics, genomics, and gene-environment interaction studies that will help fill specific knowledge gaps in the literature addressing advanced disease in patients with cancer of African descent. Additional research can be conducted, says Camille Ragin, M.P.H., Associate Director of Diversity, Equity and Inclusion at Fox Chase and co-leader and founder of AC3. .

The study involved cancer patients from Augusta University in collaboration with Fox Chase Cancer Center, Sylvester Comprehensive Cancer Center, University of Alabama, Morgan State University, and nine international AC3 research sites in the Bahamas, Barbados, Benin, and Burkina Faso. included. Haiti, Jamaica, Kenya, Namibia, Trinidad and Tobago.

“This is a huge undertaking and one that has historically been black to AC3 site leaders like Dr. Valerie Odero-Marah, co-leader of the AC3 Prostate Cancer Working Group at Morgan State University. This is only possible because of our long-standing collaboration with , and Ann Korir of the Kenya Institute of Medicine, co-leader of the AC3 Women’s Cancer Working Group.The only way this kind of collaborative effort can be achieved is , because everyone in the AC3 network plays a role and leads,” said Ragin.

“We want to enable African and Caribbean researchers to collaborate and ask questions across the United States, Africa and the Caribbean so that they can lead projects that impact our population. will be,” said George. Equity in who participates, who leads, and who is at the heart of the project. ”

About Sylvester Comprehensive Cancer Center

UHealth — Sylvester Comprehensive Cancer Center, part of the University of Miami Health System and the University of Miami Miller College of Medicine, is the only cancer center in South Florida designated by the National Cancer Institute. The NCI designation is an acknowledgment that Sylvester meets the most rigorous standards of cancer research, beginning in the laboratory and extending through patient care to meet the specific needs of the community. Sylvester is known as South Florida’s leader in patient-centered cancer research and care, with the only Phase 1 clinical trial, the first step in evaluating how patients respond to the latest investigational therapies We offer programs. The NCI designation further expands Sylvester’s ability to provide access to new therapies through more clinical trials and collaboration with other designated centers. Sylvester has a talented team of more than 2,400 oncology physicians, researchers, and support staff to discover, develop, and deliver more precise cancer treatments. To serve current and prospective patients, Sylvester has a network of conveniently located outpatient treatment facilities throughout South Florida.

About Fox Chase Cancer Center

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital, is part of Temple Health and is one of the nation’s leading comprehensive cancer centers. Founded in Philadelphia in 1904 as one of the first cancer hospitals in the United States, Fox Chase was also one of the first designated National Cancer Institute Comprehensive Cancer Centers in 1974. Center. Fox Chase researchers have won the highest awards in their field, including two Nobel Prizes. The Fox Chase physician is also regularly recognized in national rankings, and the center’s nursing program has been recognized as a Magnet of Excellence five times in a row. Today, Fox Chase conducts nationally competitive basic, translational, and clinical research with special programs in cancer prevention, detection, survivorship, and community outreach. Widely implemented. Fox Chase Cancer Center policy shall not exclude, participate in, or deny the benefit of quality health care on the basis of race, ethnicity, religion, sexual orientation, or gender. about it. gender identity/expression, disability, age, ancestry, color, national origin, physical ability, education level, or source of payment.

Post view: 13

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button